GPFA
INKT icon

Game Plan Financial Advisors’s MiNK Therapeutics INKT Stock Holding History

Game Plan Financial Advisors’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$168 Hold
16
– – ﹤0.01% 316
2025
Q4 		$178 Hold
16
– – ﹤0.01% 318
2025
Q3 		$224 Hold
16
– – ﹤0.01% 320
2025
Q2 		$118 Hold
16
– – ﹤0.01% 336
2025
Q1 		$138 Sell
16
-1
-6% -$9 ﹤0.01% 341
2024
Q4 		$116 Hold
17
– – ﹤0.01% 357
2024
Q3 		$128 Hold
17
– – ﹤0.01% 367
2024
Q2 		$161 Hold
17
– – ﹤0.01% 360
2024
Q1 		$154 Hold
17
– – ﹤0.01% 413
2023
Q4 		$182 Buy
+17
New +$177 ﹤0.01% 416

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Game Plan Financial Advisors's INKT Position: Q1 2026 in Review

Game Plan Financial Advisors held its MiNK Therapeutics (INKT) position steady in Q1 2026 at 16 shares worth $168. The position accounts for ﹤0.01% of the portfolio, ranked #316.

Game Plan Financial Advisors first reported a position in INKT in Q4 2023 and has held it in 10 quarters since. The position peaked at $224 in Q3 2025. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • Game Plan Financial Advisors held 16 shares of MiNK Therapeutics worth $168 as of Q1 2026.
  • Game Plan Financial Advisors left its MiNK Therapeutics share count unchanged in Q1 2026.
  • MiNK Therapeutics made up ﹤0.01% of Game Plan Financial Advisors's portfolio in Q1 2026, its #316 holding.
  • Game Plan Financial Advisors first reported a position in MiNK Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Game Plan Financial Advisors's MiNK Therapeutics position peaked at $224 in Q3 2025.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on Game Plan Financial Advisors's 13F filing for Q1 2026, filed 23 Apr 2026.